Telix Pharmaceuticals
39 hedge funds and large institutions have $24.5M invested in Telix Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 11 closing their positions.
189% more capital invested
Capital invested by funds: $8.47M → $24.5M (+$16M)
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
0.43% more ownership
Funds ownership: 0.33% → 0.76% (+0.43%)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 40 → 39 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$4.12M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.36M |
| 3 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$1.25M |
| 4 |
RBI
Raiffeisen Bank International
Vienna,
Austria
|
+$990K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$976K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$349K |
| 2 |
Jane Street
New York
|
-$300K |
| 3 |
QC
Quadrature Capital
London,
United Kingdom
|
-$276K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$172K |
| 5 |
Millennium Management
New York
|
-$148K |
TLX Hedge Fund Activity: Q1 2026 in Review
39 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Telix Pharmaceuticals (TLX) for Q1 2026, worth a combined $24.5M — up 189% from $8.47M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TLX and 10 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 17 added.
The largest buyer was Portolan Capital Management, opening a new position worth an estimated $4.12M. The largest seller was Marshall Wace, exiting entirely with an estimated $349K sold.
- 39 institutional investors held Telix Pharmaceuticals (TLX) as of Q1 2026, down from 40 in Q4 2025.
- Funds reported $24.5M of Telix Pharmaceuticals stock for Q1 2026, up 189% quarter-over-quarter.
- 10 funds opened new Telix Pharmaceuticals positions in Q1 2026 and 11 closed out, a net change of -1 holder.
- The largest Telix Pharmaceuticals buyer in Q1 2026 was Portolan Capital Management, an estimated $4.12M added.
- The largest Telix Pharmaceuticals seller in Q1 2026 was Marshall Wace, an estimated $349K sold.
Based on aggregated 13F filings for Q1 2026.